#Drug Manufacturers - Specialty & Generic | Explore Tumblr posts and blogs

tmr123123 · 3 years ago

Text

Global Ayurvedic Market Revenue, Regional & Country Share, Key Factors, Trends & Analysis, To 2030

Global Ayurvedic Marketwas value US$ 4.5Bn in 2017 and is expected to reach US$ 14.9Bn by 2026 at a CAGR of 16.14%.

Ayurveda is an Indian system of medicine derived from Ayurvedic natural herbs & is a form of alternative medicine. Nearly 75% of people in India use some form of traditional medicine, a category that includes Ayurveda.

Some of the driving factors favouring the market growth include growing demand for natural and organic products, increasing consumer awareness and growing demand for ayurvedic cosmetics products, expanding medical tourism through the globe. Organic skincare products are achieving fast grip and the market is expected to expand even further.

Furthermore, to expanding consumer base, anti-wrinkle & anti-ageing creams are projected to fuel the market growth. However, lack of stringent regulations and optimum therapeutics, lack of a killer instinct in the ayurvedic industry are some of the key barrier or restraint which is limiting the market size. Moreover, practical developments in ayurvedic medicines will offer great investment opportunities for players in the ayurvedic market.

Request for Sample with Complete TOC and Figures & Graphs @https://www.trendsmarketresearch.com/report/sample/4073

Personal care products segment is leading the ayurvedic market globally due to increasing awareness of personal care products, changes in consumption patterns and lifestyles, and improved the purchasing power of women, promises moving times for the personal care industry. The Asia Pacific is estimated to dominate the global market owing to the presence of established ayurvedic manufacturing units.

Retail sales are dominating the ayurvedic market. Retail is the process of selling ayurvedic product or services to customers through multiple channels of distribution to earn a profit. Retailers satisfy demand identified over a supply chain.

Region-wise, the Asia Pacific region accounts for the largest share of the market due to their rich tradition of herbal medicines led by India, Indonesia, Myanmar, Sri Lanka, and others. India is the largest market and accounts for almost US$ 1200Mn in terms of market value. India exports of Ayurvedic drugs was estimated to be around. US$ 65Mn in 2017. The main exports of Indian Ayurveda include Senna & Psyllium.

Global ayurvedic market report includes PESTLE analysis, competitive landscape, and Porterâ€™s five force model. Market attractive analysis wherein all the segments are benchmarked based on the market size, growth rate, and general attractiveness.

Direct Purchase this Market Research Report Now @https://www.trendsmarketresearch.com/checkout/4073/Single

Some of the key players operating in global ayurvedic market, Patanjali, Amrutanjan Healthcare Limited, Zandu Pharmaceuticals Works Ltd., WELEX Laboratories Pvt. Ltd, Lotus Herbals, Khadi Natural, Surya Herbal Limited.

Scope of Global Ayurvedic Market

Global Ayurvedic Market, by Mode of sales Retail Sale Online Sale

Global Ayurvedic Market, by Product Personal Care Products Hair Care & Fragrances Skin Care Oral Care Make-Up Healthcare Products Ayurvedic Medicines Ayurvedic Nutraceuticals Dietary Supplements

Global Ayurvedic Market, by Application Cancer Treatments Respiratory Disorders Mental Health Nervous System Disorders Diabetes Skin Diseases Cardiovascular Diseases Autoimmune Diseases Other Applications

Global Ayurvedic Market, by Distribution channel Supermarkets Pharmacy & Drug Stores Direct Selling Beauty Salons Specialty Stores Internet Retailing Departmental Stores Other Distribution Channels

Global Ayurvedic Market, by Region North America Europe Asia Pacific Middle East and Africa South America

Get Discount On The Purchase Of This Report @https://www.trendsmarketresearch.com/report/discount/4073

Key players operating in Ayurvedic Market Amrutanjan Healthcare Limited Zandu Pharmaceuticals Works Ltd WELEX Laboratories Pvt. Ltd Lotus Herbals Khadi Natural Surya Herbal Limited Maxcure Nutracedics Ltd. Shree Dhootapapeshwar Ltd. AVA Products & Services Vicco Laboratories Shree Baidyanath Ayurved Bhawan Pvt. Ltd. Kerala Ayurveda Ltd. Forest Essentials Dabur India Ltd. The Himalaya Drug Company Patanjali Ayurved Limited Hamdard Laboratories Emami Ltd. Charak Pharma Pvt. Ltd. BACFO Pharmaceuticals Ltd. Charak Pharma Ayurvedic LifeStyles Inc.

0 notes

dineshkarde103 · 4 years ago

Text

Global Drug of Abuse Testing Market to Witness Huge Growth From 2021 to 2028

Market Overview:

The Drug of Abuse Testing report goal to provide a clear view of the current scenario and the potential growth of the global market. The study offers a scrupulous overview of the global market by closely analyzing a range of factors relating to the Drug of Abuse Testing market, such as key segments, regional market trends, market dynamics, suitability for investment and key market players. In addition, the analysis offers sharp insights into current and future trends & developments in the global market for Drug of Abuse Testing.

Buy Any 3 And Pay For Only 2

Hurry Up To Grab This Exciting Discount...!

Offer Valid Till 31st March 2021.

Get Free Sample PDF @ https://ordientmarketresearch.com/sample-request/life-science/world-drug-of-abuse-testing-market/OMR2660

The report covers a wide range of areas for a better global market experience as well as industry trends and forecasts. The report covers market models based on product types, application regions, and key vendors. In this report, variables influencing the market such as drivers, controls, and store openings have been carefully described. The review of market models, reviews, and numbers has been done on both a large scale and a micro level. It also gives a general overview of the strategies that the main competitors have received within the company. Other important variables that influence market trends regionally and globally were taken into account. These influencing factors are the socio-political situation, environmental conditions, demographics, legal organizations, and the competitive environment in the region.

Market Scope:

The key aim of the Drug of Abuse Testing market research report is to provide insights into the success of this business space in the coming years to assist stakeholders in making reasonable decisions. In addition to the Drug of Abuse Testing industry opportunities and how they can be exploited to produce high returns, the paper includes concise information about the major trends. In addition, Drug of Abuse Testing study provides detailed discussion of the issues facing the industry and helps to establish strategies to limit their impact. In addition, the report provides a detailed review of the COVID-19 pandemic and its vertical effects on the industry.

Browse Full Premium Report @ https://ordientmarketresearch.com/life-science/world-drug-of-abuse-testing-market/OMR2660

Market Segmentation:-

The report provides important statistics on the market status of the Drug of Abuse Testing manufacturers and is a valuable guidance and guidance tool for companies and individuals interested in the industry. The report provides a basic overview of the industry including definition, applications, and manufacturing technology.

By Type

Amphetamine (AMP) Test

Methamphetamine (MET) Test

Opiates/Morphine (OPI) Test

Barbiturates (BAR) Test

Benzodiazepines (BZO) Test

Other types of reagents or strips

By Application

Medical screening

Legal or forensic information

Employment drug testing

Sports/athletics testing

Regions covered in Drug of Abuse Testing market report are:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

To Enquire About Discount Visit @ https://ordientmarketresearch.com/check-discount/life-science/world-drug-of-abuse-testing-market/OMR2660

Global Drug of Abuse Testing Market Report provide in-depth information about the Leading Competitors involved in this report:

Thermo Fisher Scientific

Siemens Medical Solutions

Alere

Firstep Bioresearch

Biopanda

BPC Biosed

MP Biomedicals

Randox Laboratories

Specialty Diagnostix

Beckman Coulter

Field Forensics

Rapid Labs

Key Points:-

Chapter 1, to describe Drug of Abuse Testing product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Drug of Abuse Testing, with price, sales, revenue and global market share of Drug of Abuse Testing in 2021 and 2028.

Chapter 3, the Drug of Abuse Testing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Drug of Abuse Testing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2021 to 2028.

Browse More Reports:

https://neighborwebsj.com/uncategorized/4736376/global-medical-chair-market-2021-to-reach-a-new-threshold-of-growth-by-2030/

https://neighborwebsj.com/uncategorized/4736385/global-electronic-packaging-market-2021-global-industry-analysis-by-trends-size-share-company-overview-growth-and-forecast-by-2030/

Mangesh Mahajan

Head of Business Development

Phone: +91-7385620197

Email: [email protected]

Web: https://ordientmarketresearch.com/

#Drug of Abuse Testing Market Size #Drug of Abuse Testing Market Share

0 notes

shraddha0330 · 4 years ago

Text

Global Drug of Abuse Testing Market to Witness Huge Growth From 2021 to 2025

Market Overview:

Buy Any 3 And Pay For Only 2

Hurry Up To Grab This Exciting Discount...!

Offer Valid Till 31st March 2021.

Get Free Sample PDF @ https://ordientmarketresearch.com/sample-request/life-science/world-drug-of-abuse-testing-market/OMR2660

Market Scope:

Browse Full Premium Report @ https://ordientmarketresearch.com/life-science/world-drug-of-abuse-testing-market/OMR2660

Market Segmentation:-

By Type

Amphetamine (AMP) Test

Methamphetamine (MET) Test

Opiates/Morphine (OPI) Test

Barbiturates (BAR) Test

Benzodiazepines (BZO) Test

Other types of reagents or strips

By Application

Medical screening

Legal or forensic information

Employment drug testing

Sports/athletics testing

Regions covered in Drug of Abuse Testing market report are:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

To Enquire About Discount Visit @ https://ordientmarketresearch.com/check-discount/life-science/world-drug-of-abuse-testing-market/OMR2660

Global Drug of Abuse Testing Market Report provide in-depth information about the Leading Competitors involved in this report:

Thermo Fisher Scientific

Siemens Medical Solutions

Alere

Firstep Bioresearch

Biopanda

BPC Biosed

MP Biomedicals

Randox Laboratories

Specialty Diagnostix

Beckman Coulter

Field Forensics

Rapid Labs

Key Points:-

Chapter 1, to describe Drug of Abuse Testing product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Drug of Abuse Testing, with price, sales, revenue and global market share of Drug of Abuse Testing in 2021 and 2030.

Chapter 3, the Drug of Abuse Testing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Drug of Abuse Testing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2021 to 2030.

Browse More Reports:

Global Potassium Sulphate Market 2021 Industry Demand Share Trend And Research Methodology By Forecast To 2028 1

Global Silicone Crosslinked Polyethylene Market Research Report 2021

Mangesh Mahajan

Head of Business Development

Phone: +91-7385620197

Email: [email protected]

Web: https://ordientmarketresearch.com/

#Drug of Abuse Testing Market Size

0 notes

blogwiseguy123world · 4 years ago

Text

Global E-Pharmacies Market- Industry Analysis, Size, Share, Growth, Trends and Forecast - 2019-2026

Summary – A new market study, titled "Report keyword" has been featured on WiseGuyReports.

Global e-pharmacies market is expected to grow at a CAGR of XX% to reach a market value of USD XXX million by 2026. E-Pharmacies are internet based vendor, delivers medicines and medical products at your doorsteps. In most of the cases, the prescriptions can be communicated through an electronic medium to get the medicines dispensed, which helped in the transformation of the conventional drug dispensing or retail pharmacy management. The goal of e-pharmacy other than improving patient care and safety is to reduce racial and ethnic disparities. The advantages provided by e-pharmacies compared with retail stores include convenience, cost-effective, accessibility and generic medicines. Also read – https://www.medgadget.com/2020/08/e-pharmacies-2020-effect-of-covid-19- market-analysis-company-profiles-and-industrial-overview-research-report-forecasting-to- 2026.html Market Drivers: Benefits provided by e-pharmacies such as availability of medicines at affordable prices, access to information on the prescribed data, shift towards self-diagnosing from the direct doctor- patient relations and increase in digital health is driving the e-pharmacies market, and is also

expected to remain high over the forecast period. Huge discounts from e-commerce companies have lured consumers to shop more than required. E-pharmacies can save as much as 95% on medication compared with local pharmacies. Market restraints: Increase in the number of illegal online pharmacies is hindering the global e-pharmacies market. According to Alliance For Safe Online Research in 2018 claims that each month 600 new illegal pharmacies are launched globally and does not follow government regulations. Market Segmentation By product type he global e-pharmacies market is segmented on drug type includes over the counter and prescription. Prescription drugs dominate the global e-pharmacies market due to its increase in chronic disease prevalence , extensive usage and increase in geriatric population and it is expected to remain high during the forecast period. According to the study conducted by Pharmacy Checker in 2015, it was found that 4 million Americans imported prescription medicine through e-pharmacies because of cost. By geography North America dominates the global E-pharmacies market in 2018, due to the high number of internet users and high adaptability to online services. India is the fastest growing market in Asia Pacific region for global E-pharmacies market due to an increase in a number of e-pharmacies, cost-effectiveness and fast track delivery at doorsteps, and expected to rise during the forecast period. According to the Internet And Mobile Association of India in December 2017, India is estimated to have more than 481 million active users and ranks 13th in the global e-pharmacy in terms of value and 3rd in terms of volume. According to the study conducted by Consumer Online Foundation And The Bureau Of Research On Industry And Economic Fundamentals in July 2016 found that in India 2/3rd of consumers prefer to order medicines online and the majority of the age group that orders online are between 55-74 years. The majority of consumers quoted that low prices and discounts and savings on purchases would be the biggest advantage. Competitive Landscape Merger and acquisitions between major e-commerce sites and e-pharmacies to enhance their service are driving the global E-pharmacy market. In September 2018, NetMeds acquired telemedicine portal JustDoc in a cash-and-stock deal and received $35 million on Series C funding from Daun penh’s investment holding, Singapore. In July 2018, Amazon acquired Pillpack online pharmacy for less than $1 billion. In November 2018, Medlife acquired health tech startup Eclinic 24/7 for e-pharma expansion. In September 2017, 1mg technologies pvt.ltd acquired Varanasi based healthcare startup dawailelo.com. In December 2016, 1mg technologies Pvt. Ltd has acquired Mumbai based MediAngels to enter into specialty doctor consultations, corporate health services, and insurance partnerships. In July 2016, Walgreens invested $416 million in Chinese pharmacy chain Sinopharm Gouda. Target Audience • Raw Material Suppliers/ Buyers

• Product Suppliers/ Buyers • Industry Investors/Investment Bankers • Education & Research Institutes • Research Professionals • Emerging Companies • Manufacturer

For more details - https://www.wiseguyreports.com/reports/3792036-global-e-pharmacies- market-2019-2026

About Us: Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Contact Us: NORAH TRENT [email protected] Ph: +162-825-80070 (US) Ph: +44 2035002763 (UK)

0 notes

marketreasearch · 4 years ago

Text

Global CHRONIC BRONCHITIS market Growth Opportunities, Industry Analysis, Size, Share, Geographic Segmentation & Competitive Landscape Report to 2026

Global CHRONIC BRONCHITIS market report explains better market perspective in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. Moreover, this CHRONIC BRONCHITIS market report underlines plentiful factors such as general market conditions, trends, inclinations, key players, opportunities, and geographical analysis which all aids to take business towards the growth and success. The CHRONIC BRONCHITIS report brings into focus, the more important aspects of the market or ABC industry. This report provides the broader perspective of the market place with its comprehensive market insights and analysis which eases surviving and succeeding in the market.

Market Analysis and Insights: Global Chronic Bronchitis Market

Chronic bronchitis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of allergic reactions worldwide and emerging markets are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chronic-bronchitis-market

Competitive Landscape and Chronic Bronchitis Market Share Analysis

Global chronic bronchitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to chronic bronchitis market.

The major players covered in the chronic bronchitis market are Sun Pharmaceutical Industries Ltd., Cipla Inc., Nephron Pharmaceuticals Corporation, Hikma Pharmaceutical PLC, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries Ltd., Apotex Inc., and Boehringer Ingelheim International GmbH among others.

Market Drivers and Restraints:

Growing cases of asthma and COPD which causes severe coughing problem drives the chronic bronchitis market. However, rise in number of patients suffering from COPD, increased cigarettes smoking and increased industries chemical pollutants, smog, toxic chemical fumes in environment will boost up the global chronic bronchitis market. Furthermore, lack of patient’s awareness and pharmaceutical patent expiry may hamper the global chronic bronchitis market.

Chronic bronchitis is the inflammation condition with long-term swelling and irritation in the air passages. Over the time symptoms get worsen and causes serious lungs damage and sometime its permanent. The cough lasting from three months occurs within a life span of 2years. Chronic bronchitis is majorly associated with smoking and type of chronic obstructive pulmonary disease (COPD).

Chronic bronchitis market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-chronic-bronchitis-market

Global Chronic Bronchitis Market Scope and Market Size

The chronic bronchitis market is segmented on the basis of treatment type, drug class, route of administration, end-users and distribution channel.

On the basis of treatment type, the chronic bronchitis market is segmented into pharmacological, nonpharmacological and others

On the basis of drug class, the chronic bronchitis market is segmented into bronchodilators, glucocorticoids, antibiotic, phosphodiesterase-4 inhibitors and others

Route of administration segment of chronic bronchitis market is segmented into oral, parenteral, inhalational and others

On the basis of end-users, the chronic bronchitis market is segmented into hospitals, specialty clinics and others

On the basis of distribution channel, the chronic bronchitis market has also been segmented into hospital pharmacy, retail pharmacy others

Chronic Bronchitis Market Country Level Analysis

Global chronic bronchitis is analysed and market size information is provided by country, treatment type, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Chronic bronchitis market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Geographically, North America holds the largest market share due to increasing infection in geriatric population, and growing population with smoking habits. Europe is considered second largest market for chronic bronchitis due to increased initiatives taken by the pharmaceutical organizations to generate novel formulation. Asia-Pacific is expected to account for the largest market share over coming years for the Chronic bronchitis market due to increased prevalence of COPD, asthma and other lungs diseases and increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global chronic bronchitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Chapters to deeply display the Global Chronic Bronchitis market.

Introduction about Chronic Bronchitis

Chronic Bronchitis Market Size (Sales) Market Share by Type (Product Category) in 2019

Chronic Bronchitis Market by Application/End Users

Chronic Bronchitis Sales (Volume) and Market Share Comparison by Applications

(2020-2027 ) table defined for each application/end-users

Chronic Bronchitis Sales and Growth Rate (2020-2027)

Chronic Bronchitis Competition by Players/Suppliers, Region, Type and Application

Chronic Bronchitis (Volume, Value and Sales Price) table defined for each geographic region defined.

Chronic Bronchitis Players/Suppliers Profiles and Sales Data ……………..

Additionally Company Basic Information, Manufacturing Base and Competitors list is being provided for each listed manufacturers

Market Sales, Revenue, Price and Gross Margin table for each product type which include , Product Type I, Product Type II & Product Type III

Chronic Bronchitis Manufacturing Cost Analysis

Chronic Bronchitis Key Raw Materials Analysis

Chronic Bronchitis Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis

Market Forecast (2020-2027)

……..and more in complete table of Contents

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-chronic-bronchitis-market

Key questions answered in this report

What will the market size be in 2027 and what will the growth rate be

What are the key market trends?

What is driving Chronic Bronchitis Market?

What are the challenges to market growth?

Who are the key vendors in Market space?

What are the key market trends impacting the growth of the Chronic Bronchitis Market?

What are the key outcomes of the five forces analysis of the Chronic Bronchitis Market?

What are the market opportunities and threats faced by the vendors in the Chronic Bronchitis market? Get in-depth details about factors influencing the market shares of the Americas, APAC, and EMEA?

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[email protected]

0 notes

databridgemarketresearchblog · 4 years ago

Text

Osteoarthritis Treatment Market 2020 Explosive Growth | Global Players - Sanofi, Zyla Life Sciences, Novartis AG, Johnson & Johnson Services, Inc, Merch & Co., Inc, Eli Lilly and Company, Abbott

Market Analysis and Insights: Global Osteoarthritis Treatment Market

Global osteoarthritis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-osteoarthritis-treatment-market

The market dynamics study of this Osteoarthritis Treatment Market business research report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions different regions i.e. the geographical spread of the business. Under competitive market share evaluation, this document suggests that the key players dominate the operations in the industry attributable to their strong geographical reach & huge production facilities. The major players operating in the Osteoarthritis Treatment Market are in strong competition in terms of technology, innovation, and pricing.

The major players covered in the global osteoarthritis treatment market are Bayer AG, Pfizer Inc., Sanofi, Zyla Life Sciences, Novartis AG, Johnson & Johnson Services, Inc, Merch & Co., Inc, Eli Lilly and Company, Abbott, ABIOGEN PHARMA S.p.A., Ampio Pharmaceuticals Inc and others.

Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-osteoarthritis-treatment-market

The growth of osteoarthritis treatment market enhanced by the growing cases of osteoarthritis treatment which create an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and presence of well-established healthcare facilities are some of the impacting factors for the demand drugs. Nevertheless, huge financial burden and patent expiration are the factors that hinder the growth of this market.

Osteoarthritis is also termed as degenerative joint disorders is the most common type of the arthritis which usually seen in geriatric population. It is occurring when protective tissue cartilage presents at the end of the bone are gradually wearing down and may worsen over a time.

Osteoarthritis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Osteoarthritis Treatment Market Scope and Market Size

Osteoarthritis treatment market is segmented on the basis of type, treatment type, route of administration, end-users and distribution channel.

On the basis of type, the global osteoarthritis treatment market is segmented into hip osteoarthritis, spinal osteoarthritis and others.

Based on treatment type, the global osteoarthritis treatment market is segmented into medication, surgery and therapy.

Route of administration segment for global osteoarthritis treatment market is categorized into oral, parenteral and others.

On the basis of end-users, the global osteoarthritis treatment market is segmented into hospitals, homecare, specialty clinics and others.

On the basis of distribution channel, the global osteoarthritis treatment market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Global Osteoarthritis Treatment Market Country Level Analysis

Global osteoarthritis treatment market is analyzed and market size information is provided by country, type, treatment type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global osteoarthritis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Among regions, North America has been witnessing a positive growth for osteoarthritis treatment market throughout the forecasted period owing to the global leaders in research and development activities, vulnerable obesity population and increase in cases of osteoarthritis. Europe is considered a second largest growing regional segment due to the presence of refined healthcare infrastructure and high diagnostic rate. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

Patient Epidemiology Analysis

Global osteoarthritis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Osteoarthritis Treatment Market Share Analysis

Global osteoarthritis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to osteoarthritis treatment market.

Customization Available: Global Osteoarthritis Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

To Get This Report at an Attractive Cost, Click Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-osteoarthritis-treatment-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail: [email protected]

#Osteoarthritis Treatment Market

1 note · View note

addictionfreedom · 6 years ago

Text

Suboxone Treatment Dayton Ohio

Contents

Provide medicated assisted treatment

Complete contact information including

Dayton. (937) 262-3500. community counseling

Drugs. Detox. Treatment Centers. Home Suboxone Clinics Ohio. Chat Let's Talk: Click To Chat Call Now: 24Hr Addiction Hotline 800-721-8114 Email We'll Call You: Contact Us. Suboxone Clinics by cities of Ohio. Call800-721-8114and get help today!

Suboxone Doctors Helping Dayton Ohio Communities With Addiction Recovery. Dayton Recovery: (937) 813-0888 Vandalia Recovery: (937) 789-4660. "Convicted drug dealer charged in case with 'buck naked' fentanyl" – Dayton Daily News. "Mass-Casualty Event: Ohio County Now Tops U.S. In…

who practices and teaches family medicine at Wright State University outside of Dayton. "They know more about what marijuana will do for their chronic pain and addiction problems than we do." Leeds is …

Farthest along is a facility called Brigid’s Path near Dayton, Ohio, that is scheduled to open in April 2017. Nationwide, the number of pregnant women using heroin, prescription opioids or addiction t…

Buprenorphine Opioid Treatment Doctors in Dayton, Ohio. Suboxone® is the first narcotic drug available for prescription from a doctor's office for use in the treatment of opioid dependence under the Drug Addiction Treatment Act of 2000 or DATA 2000.

Today, he sits casually in a white plastic chair at Groups, the treatment center that he credits with … “Middletown is stuck in between two major cities. Dayton is the drug capital of Ohio. It’s eas…

10 Outpatient Alcohol Treatment Centers in Dayton, Ohio …. insomnia, PTSD resulting in alcoholism; Buprenorphine and suboxone treatment services.

Heroin treatment centers in Dayton, Ohio can help you, or your mother, father, son, daughter or loved one end abuse by providing the help you need in a��…

Results 1 – 9 of 730 … Find certified physicians and opioid rehab treatment centers/clinics in Ohio … Suboxone Doctor Results – Ohio … Dayton, Ohio, United States.

Dayton Drug & Alcohol Rehab, Detox & Treatment Resources. Dayton, the birthplace of Orville Wright, is also home to the National Museum of According to the Ohio Department of Health, the number of fentanyl-related deaths in the state rose from 84 in 2013 to 503 in 2014 and then again to 1,155 in 2015.

Being recognized as Dayton Ohio's premier provider for Suboxone treatment hasn't been a result of simply treating the addiction of our patients, but rather a result of treating the underlying issues beneath the stem of that person's addiction is what continues to be the driving factor towards helping…

We provide Methadone and suboxone treatment along with individual counseling. Oklahoma treatment services is here to take the first step to a better life with you. We understand the disease of addiction, and we aim to better the lives of those who have been impacted by addiction.

Crack Movie Wiki Akshay Kumar Crack Movie 2018 – MT Wiki providing Latest Star cast and crew, release date MT Wiki: Upcoming Movie, Hindi TV Shows, Serials TRP, Bollywood Box Office: Crack 2018: Movie Full… Logan and Noah Miller have written the film based on the true story of Rick Wershe Jr who was 15 when he was Addiction Treatment Grand Rapids Mi Buprenorphine Opioid Treatment Doctors in Grand Rapids, Michigan. While these treatments have been available for many years, there is a stigma to relying on these medications to help fight addiction rather than the traditional willpower and community approach of a 12-step program. Top Grand Rapids, Addiction Recovery Centers: Reviews and Ratings. When you are putting

BrightView's treatment program includes a comprehensive plan for symptom management, medical and psychological … 100% of Ohio Medicaid Plans …

However, SUBOXONE Film may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone. Keep SUBOXONE Film out of the sight and reach of children.

Located in Dayton, Ohio and licensed by OMHAS, Access Residential is an inpatient treatment facility specializing in the treatment of adults with substance …

Jul 26, 2018 … Home › Ohio Drug And Alcohol Addiction Treatment › Dayton Drug And … has decreased in Dayton, illicit Suboxone (buprenorphine) use is on …

DeCoach Rehabilitation Centre specializes in providing Medication-Assisted Treatment (MAT) for alcohol and opiate addiction including dependence on heroin …

COLUMBUS Attorney General Mike DeWine is suing five drug-manufacturers for flooding Ohio … treatment. "At the same time we must realize there are some pharmaceutical companies that have sought solut…

Feb 8, 2018 … VANDALIA, Ohio (WKEF/WRGT)- Dayton Treatment Services is now opened in … Regional Director says they provide medicated assisted treatment. … "We primarily utilize methadone and suboxone for individuals that are …

87 results … A default suboxone clinic picture. 4100 West Third St., Building 302, Room 125. Dayton, OH 45428. 17.94 mi away. Please call for availability

PROCEDURES Baseline rectal temperature, heart rate, and respiratory rate were recorded prior to premedication with buprenorphine (0.02 mg/kg … (REF403), Measurement Specialties Inc, Dayton, Ohio. c. …

Poor Glinda was very frustrated with the current system of treatment for drug abusers … This program had been in place since 1960 in Dayton, Ohio, until about 5 years ago when drug companies came ou…

Please call (513) 487-6662 for information about participating in these trials in either Cincinnati or Dayton. CinARC also collaborates with six regional community treatment programs, which make up th…

The Suboxone Directory. Opiate Addiction Treatment Using Suboxone. Suboxone has been proven to be quite an effective opiate addiction treatment. There are numerous Suboxone detox centers all over the country that assist addicts in overcoming their addiction.

Find Treatment Centers near me that prescribe Methadone and Suboxone for detox from opioid abuse/addiction accepting new patients, Medicaid and other insurance..

The Ohio Department of Medicaid couldn't provide data on how much it spends on … Suboxone, the brand name for one of the treatment drugs, is being sold or …

OBJECTIVES: To compare pharmacologic treatment strategies for neonatal … Neonatology groups representing each of the 6 Ohio children’s hospitals (Akron Children’s Hospital, Cincinnati Children’s Hos…

Dayton. Ohio Treatment for Professionals. Ohio Executives Drug & Alcohol Rehab Centers. Here is a list of the different treatment centers using suboxone in Ohio. The list can be incomplete so please do not hesitate to contact one of our counselors at 1-800-304-2219.

who practices and teaches family medicine at Wright State University outside of Dayton. “They know more about what marijuana will do for their chronic pain and addiction problems than we do.” Leeds is …

The data continued to roll in as city after city adopted the policy; Baltimore, Maryland, Dayton, Ohio, Orlando Florida … bipartisan-bill-to-fight-opioid-epidemic?amp=1 21) Treatment with Suboxone F…

Farthest along is a facility called Brigid’s Path near Dayton, Ohio, that is slated to open in April 2017. Nationwide, the number of pregnant women using heroin, prescription opioids or addiction trea…

Media outlets also report on safe injection site studies, recovery help for moms and babies; spikes in fentanyl-related deaths; training for dispensing naloxone, treatment in jails … recovery center …

Find Suboxone Doctors near me in Dayton, Ohio for detox from opioid abuse/ addiction accepting … Treatment Services: Addiction, Buprenorphine, Suboxone.

Suboxone Doctors – Helping Dayton Ohio Communities With Addiction Recovery. Dayton Recovery: (937) 813-0888 Vandalia Recovery: (937) 789-4660. Suboxone treatment and substance abuse therapy for addiction to heroin and pain killers. We offer counseling and doctor consultation with each…

Woodhaven Drug & Alcohol Treatment – 1 Elizabeth Pl., Dayton 45417. 937-461- 5223 … These are agencies who are certified by Ohio Department of Mental Health & Addictions Services, a … S=Suboxone; V=Vivitrol. 1, 3. 1, 2, 3, 4. 1, 3. 3. 1, 3.

Addiction Treatment Programs In Florida We have become one of the top alcohol & drug rehabs in Florida providing inpatient treatment with a true gender-specific model & a co-ed intensive outpatient … South Florida Museum officials later acknowledged after the conclusion … The biggest message that the aquarium director said she wants to pass on to visitors is that there is

With offices in a building known as the Ice House (one of its former uses), CinARC conducts clinical trials in the Cincinnati and Dayton areas … between community treatment providers and academic re…

"NORML hopes that he finds the time during his retirement to seek treatment … Five out of six Ohio localities that had decriminalization measures on their local ballots approved them. Decriminalizat…

Addiction Treatment Marketing marketing addiction treatment services can be nearly as hard as providing help to break addictions. The people who need your services most are likely to be in denial or ashamed of their problem. The Addiction Web Marketing Pros Redefine "Web Success" for the Private-Pay & PPO Segments Utilizing our vast expertise in the fields of

Welcome to the Suboxone Treatment Directory for Ohio. Below is a list of Suboxone treatment programs and doctors who prescribe Suboxone in Ohio. The listings are sorted alphabetically by city/town. Each listing provides complete contact information including name, address, phone number…

Suboxone Doctors provide Buprenorphine and Suboxone treatment services to opioid addicts who are addicted to a narcotic drug including heroin, OxyContin, Dilaudid, morphine, Vicodin and other opiate prescription pain medications.

Treatment Options. Suboxone and Vivitrol are two drugs used at Southwest Ohio Physicians to help people addicted to opiates like pain killers and heroin in our south Dayton office.

Suboxone treatment has a high success rate in treating opiate dependence, and SORG Cincinnati West is proud to be a top-rated Suboxone clinic in the Western Cincinnati area. Our drug rehab clinic serves all of Ohio, including Dayton, Indiana and Kentucky.

Addiction Treatment Centres In The Uk Google has removed search ads related to addiction treatment in the UK, following an investigation by The Sunday … on the terms and receiving large kickbacks from the private centers where the searc… The advertising behemoth began gradually limiting advertising for the addiction treatment center category in the US in September of 2017, and by

Dayton Drug Rehab. Treatment Centers Ohio. Rehabs In Ohio. Learn more about Lumiere's fully comprehensive treatment and recovery programs to see why we are the premier provider for addiction treatment in the Greater Cincinnati, Ohio area.

Public Health Addiction Services provides substance abuse treatment, problem … Public Health – Dayton & Montgomery County's Addiction Services provides … Our 3 tracks (Suboxone to Vivitrol, Vivitrol Only, or medication free) have no specific …. Problem Gambling Prevention Coalition; Ohio Substance Abuse Monitoring …

Colorado Treatment Services provides methadone and suboxone treatment for those suffering from an opioid addiction. Colorado treatment services is here to take the first step to a better life with you. We understand the disease of addiction, and we aim to better the lives of those who have been…

dayton. (937) 262-3500. community counseling and Treatment Services, Inc. Ohio has its methadone clinics and (buprenorphine) suboxone doctors concentrated mostly in and around its metropolitan urban centers. Ohio Buprenorphine Suboxone Doctors. James Edgar Phillips, M.D.

0 notes

brooklyntobangalore · 7 years ago

Text

Pain & Palliative Medicine Rotation

I spent Weeks 4 and 5 with the Pain & Palliative Medicine Department. It was an opportunity to engage with issues pertaining to end-of-life care and to see how culture and class influence medical decision-making for patients with terminal illness. Palliative medicine is a relatively new sub-specialty in India; it didn’t become its own distinct department at St. John’s until 2008. Most low- and middle-income countries, India included, still have little access to palliative care. The St. John’s website describes the philosophy of Palliative Medicine as follows 1:

��Palliative Medicine is a multidisciplinary approach to specialized medical care for people with life-limiting illnesses. It focuses on providing people with relief from the symptoms, pain, physical stress, and mental stress of the terminal diagnosis. The goal of such therapy is to improve quality of life for both the person and their family.”

As such, the focus is on holistic symptom management (esp. pain management) and improving quality of life, rather than on curative interventions – a concept that several attendings remarked is still difficult for patients and families in India (or in the U.S., for that matter…) to accept. Palliative Medicine is a consultative service for the most part, and a majority of the terminal inpatients we rounded on were cancer patients. Still, approx. 80% of the caseload consisted solely of pain management for non-terminal patients – an indication, according to our attending Dr. T, that palliative care is still under-utilized as a service.

The nature of the specialty means that witnessing tragedy is inevitable: a 38 year old lady battling Stage IV ovarian cancer for years and finally succumbing; a small 6 year old boy with an aggressive form of metastatic Wilm’s tumor; colon cancer causing bowel obstruction and extreme abdominal pain; lung cancer making breathing difficult. The families by and large handled their adversity with grace, and I was often moved to see them advocate for their loved ones so adamantly – to ensure that pain and suffering would be minimized even if a cure was elusive or impossible.

Pain management was an important aspect of daily rounds; a lot of care was taken to ensure that dosages of pain meds (usu. opioids) were appropriately titrated. The Palliative team followed the so-called ‘WHO Ladder’ for pain management, whereby pain meds would be escalated from non-opioids (ex. NSAIDS, paracetamol) to weak opioids (ex. tramadol) to strong opioids (ex. morphine, fentanyl) in a stepwise fashion. Given the seriousness of the current opioid crisis in the U.S., this made me wonder about how opioids and other drugs were regulated in India. According to one of the attendings, the Indian Narcotics Bureau designates only certain hospitals as being able to prescribe strong opioids. And within each institution, only Registered Medical Practitioners (RMPs) who have received special training/certification can prescribe opioid medications. Kerala has the most opioid-dispensing institutions (~100-150), with North India having significantly fewer (only a few dozen, according to Dr. T). Bangalore has eight, of which St. John’s is one. There is an interesting tension between wanting to minimize patient exposure to the risk of narcotic dependence on the one hand whilst also striving to ensure that patients have appropriate access to pain meds on the other. A few patients we saw had actually come to St. John’s from out-of-state because they couldn’t otherwise obtain prescriptions for oral morphine 2 to manage their chronic pain 3.

Complicating things further, Dr. T also noted that titrating pain meds was sometimes frustrating because many of the pharma companies that produce generic meds aren’t strictly regulated and have questionable quality assurance. As a result, you can’t always be certain whether a particular drug/pill contains the full listed dose. Thus, if a patient doesn’t respond to a particular dosage/regimen, it’s often unclear whether it’s due to lack of efficacy or whether the pill the patient was given simply doesn’t contain the proper dose. One patient who was given tramadol in its generic form continued to complain of persistent pain; instead of upping the dose, Dr. T decided to try switching to a brand name formulation, and the patient’s pain immediately came down. Referring to some of the generic formulations of commonly prescribed oral pain meds, Dr. T wryly mused, “Is it chalk powder? It could be chalk powder. We don’t know.” On top of all this, the Indian government actively applies pressure on MDs to prescribe generics as a cost-saving measure, to the consternation of doctors, who argue that they cannot possibly provide optimum care if they can’t even be sure of the contents of the generics they are pressured to prescribe.

This got me wondering about how generics were regulated in the U.S., given that many of the generic meds that we prescribe and use are manufactured and sourced abroad in places like India. How does the U.S. ensure that our own markets aren’t flooded with questionable generics? I did some quick digging, and it seems that in order for foreign manufacturers to export their product to the U.S., they have to pass muster with the FDA’s Drug Quality Sampling and Testing Program 4. According to Consumer Reports: “...inspectors from the U.S. and India have ramped up efforts to make sure that plants in India making the drugs exported to the U.S. adhere to the strict manufacturing standards and regulations required by the FDA” 5. As much as we love to collectively complain about inefficient government bureaucracy, these revelations have made me grateful that we have institutions in place to ensure the public interest, as a check on rapacious private commercial practices.

Maybe the biggest takeaway from this rotation was how starkly it underscored inequalities in healthcare access. Unless a patient is very wealthy, healthcare (and esp. care for terminal illness) is often financially ruinous. Every citizen has access to free care at government hospitals, of course, but the general consensus is that these public facilities are under-resourced, under-staffed, and sub-par in terms of care quality. Many patients who can afford to do so therefore seek care at private facilities like St. John’s, where they pay out-of-pocket for every service rendered. Services can be abruptly halted if bills aren’t promptly paid. One patient with Stage III cervical cancer had her chemo and IV pain meds discontinued because of unpaid bills totalling 80,000 Rs. The mother of the aforementioned boy with metastatic Wilm’s tumor had apparently sold land and taken out loans to fund the treatment of her son, only to find out that the tumor was incurable. How she will manage financially after her son passes is unclear. In a market-based, for-profit system like India’s, are there ways to ensure greater healthcare equity and to make access less dependent on individual or familial wealth? 6

++++++++++++++++

[1] See: http://www.stjohns.in/Departments/Palliative%20Medicine/Overview ↩︎

[2] An interesting factoid: oral morphine is ridiculously cheap here – only ~1-2 Rs per pill! ↩︎

[3] Although the question of whether and to what extent opioids should be used to manage chronic pain in the first place is a contentious one. ↩︎

[4] See: https://www.fda.gov/Drugs/ScienceResearch/ucm407277.htm ↩︎

[5] See: https://www.consumerreports.org/cro/news/2014/04/are-generic-drugs-made-in-india-safe/index.htm ↩︎

[6] As with healthcare in the U.S., the problems and their solutions are, in part, a function of politics and political will. India spends less than 2% of its GDP on healthcare, and there is no robust system of health insurance to ensure high quality healthcare for all of its citizens. Certainly greater public sector investment in healthcare could be part of the solution. ↩︎

0 notes

saltyloverrebel · 7 years ago

Text

Dr Reckeweg R41 Drops, Top Homeopathy Impotence Medicine

Dr Reckeweg R41 Drops, Top Homeopathy Impotence Medicine is a best selling German homeopathic remedy for lack of sexual energy and strength, loss of erectile power (ED), loss of semen during urination or stool & sleep (spermatorrhoea), general debility especially in men. R41 helps recover from weakness after debilitating illnesses, physical overwork, over excitement, & nervous exhaustion. The…

View On WordPress

0 notes

alphst · 2 years ago

Text

CRESCO LABS INC-SUBORDINATE (CL) Q1 2023 Earnings Call Transcript

CRESCO LABS INC-SUBORDINATE (PNK : CL) Q1 2023 Earnings Call dated May. 24, 2023. Corporate Participants: Megan Kulick — Senior Vice President, Investor Relations Charles Bachtell — Chief Executive Officer and Co-Founder Dennis Olis — Chief Financial Officer Analysts: Aaron Grey — Alliance Global Partners — Analyst Scott Fortune — Roth MKM — Analyst Andrew Partheniou — Stifel — Analyst Greg…

View On WordPress

#Drug Manufacturers—Specialty & Generic #Healthcare

0 notes

veritysolutions-blog · 7 years ago

Photo

340B Overview by Verity Solutions - www.verity340B.com

Verity 340B Solutions: Manage your 340B Program and stay compliant with Verity 340B Solutions

The 340B Drug Pricing Program provides big benefits to healthcare providers and patients. But it also comes with its own set of challenges. With increasing complexity and demand for audit preparedness, covered entities are having a tougher time managing the program and staying compliant. It’s now more important than ever to have the right solution and the right partner to help your organization stay on top of 340B. That’s where Verity Solutions comes in. At Verity we can help you maximize the performance and agility of your 340B program with a host of product offerings designed to help you foster compliance, respond quickly to changing regulations and maximize your savings. Hundreds of health systems rely on Verity 340B products to maintain compliance, maximize savings, minimize WAC spend and keep them up-to-date with ever-changing rules and regulations.

What 340B is and how it works

Before we get into how Verity Solutions can help companies optimize and remain compliant with 340B, let’s look go over exactly what the program entails. In 1992, the US Federal Government created the 340B Drug Pricing Program. It requires drug manufacturers, through the signed Pharmaceutical Pricing Agreement (PPA) with the secretary of the Department of Health and Human Services (HHS) specified under Section 340B, to provide discounts on outpatient drugs to select safety net providers or eligible health care organizations and covered entities, including Federally Qualified Health Centers. This is to serve the nation’s most vulnerable patient populations. It is made to promote quality assurance and access to affordable medications.

Drugs with the discounted prices can either be available through the respective covered entity’s wholesaler or another channel dependent on the manufacturer. Covered entities can give drugs that they have bought under 340B through to any eligible patient no matter what their payer status or whether the drug is for clinical use or to be self-administered.

Furthermore, manufacturers are expected to offer bigger discounts on single-source and brand-name drugs with generic competition if their best price for a drug is less than the AMP minus 23.1% or if the drug has increased more quickly than the rate of inflation.

How Can Companies Remain Compliant with the Program?

For companies treated as covered entities under the 340B program, it is imperative to provide the kind of quality care patients deserve. With the 340B program, covered entities can give this at a much affordable price. However, any infraction of the rules could lead to penalties that are not only costly but bad for the reputation of the company as well. To avoid this, here are four key elements for companies to remain compliant with the program:

1. Patient Eligibility – It is a must to ensure the eligibility of a patient accepting the discounted outpatient drugs. 340B products must not be given to non-qualifying patients. It is illegal for covered entities to sell and distribute medications under the 340B program to those who are not considered as patients.

2. Anti-Diversion – To ensure that the dispensing of discounted outpatient drugs under the 340B Program is within the rules, companies or covered entities must have an inventory or an audit trail to trace the purchase and pick-up by the patient. The 340B Program regulates the prohibition of diversion of these drugs to non-patients, ineligible facilities within the same facility, and excluded services of the covered entity. Other potential diversion risk areas include security and theft risks.

3. Medicaid Pricing Requirements – Section 340B requires the invoice price to be reflected the acquisition cost plus State approved fees at the time of purchase. It should be noted that dispensing fees and other billing calculation factors might vary by state.

4. Double-Dipping – This complies with the “Double-Dipping” Prohibition of the State Medicaid Cost Rebate Verification. Covered entities must report outpatient pharmacy Medicaid provider numbers to prevent double dipping of rebate. “Double-dipping” happens when a state seeks a Medicaid rebate on the same unit of drug that a manufacturer sold to the covered entity at a discounted price under the 340B program.

The 340B Program’s double-dipping prohibition places obligations on both the covered entity and the state to ensure that, with respect to 340B drugs dispensed to Medicaid beneficiaries, the manufacturer incurs either the 340B discount at the time of the covered entity’s purchase or a later Medicaid rebate to the state, but not both.

Verity 340B helps organizations stay compliant

Our software has the following features that help to ensure that covered entities remain 340B compliant at all times.

Verity Solutions 340B Audit and Compliance Services

HRSA regularly audits covered entities to monitor 340B compliance, which requires those entities to adhere to program regulations and guidelines. With Verity Solutions 340B Audit and compliance services, you can spend less time worrying about them. Our experts simplify your compliance with an end-to-end audit program that includes:

Verification of eligibility (including GPO and outpatient clinic eligibility

A review of relevant policies and procedures and how they are utilized in your organization

Verification of your internal controls to prevent duplicate discounts

A compliance review of your contract pharmacy relationships.

We can even be on-site to help you through HRSA and manufacturer audits every step of the way.

Verity Solutions 340B Compliance Manager

HRSA audits are increasing in frequency and scope and today’s auditors are applying even more pharmacy expertise to their reviews. As a result, covered entities are more at risk for costly remediation and removal from the 340B program than ever before. You need absolute certainty that you have a reliable compliance framework and tracking tools to ensure consistent implementation of your policies and procedures across your organization. Our web-based compliance portal stores your program documentation and gives you the tools to fulfill your self-audit requirements quickly and easily, regardless of which 340B administrator you use.

Verity Solutions Compliance Manager features include

A comprehensive library of compliance tasks and policies written by 340B experts with recommended activities and templates, assessment steps and review criteria

Notifications that tell you where tasks are at, who’s doing them and when they are due, and inform you on their unique risk factors.

Executive reports and metrics

A user-friendly dashboard with compliance information at a glance.

With Verity Solutions 340B Compliance Manager, maintaining your 340B program compliance has never been easier.

Verity 340B helps covered entities save even more money

Our solutions can also help covered entities save money and improve their process thanks to these features:

Split Billing

Verity Solutions Split Billing can simplify your 340B program and optimize your savings for qualified transactions while helping you maintain compliance. Every covered entity can benefit from our solution as it is compatible with all major wholesale vendor order-entry and hospital information systems. You can automatically split replenishment orders for medications into as many accounts as necessary to meet your individual needs and match pharmaceutical usage with wholesale order quantities to maximize savings. Access on-demand reports, dashboards and application tools for full visibility into your 340B program and innovative features like best price logic, CDM mapping alerts, package size recommendation tools and central distribution support. Ultimately, it helps to simplify your order process and eliminate the need for labor-intensive separate invoices.

A fully managed service

youtube

With the Verity Solutions 340B managed services offering, our dedicated experts can help you manage your 340B program using our advanced software platform. Our team will help you take advantage of every possible saving opportunity while maintaining full compliance and audit readiness. Our team will manage the key details of your 340B program so you don’t have to. As a result, we can help you maximize savings and minimize WAC spend. Don’t think you won’t know what’s going on, however. Our reports, dashboards and application tools provide full visibility into your 340B program. With our managed service, you can rest assured that your 340B software is up-to-date with the latest compliance regulations.

Contract pharmacy program

Under the 340B Drug Pricing Program, you can partner with pharmacies within your community to dispense eligible prescriptions on your behalf, which lets your organization access additional savings while providing patients with convenient access to the drugs they need.

Establishing and maintaining these relationships is a complex task. That’s where Verity 340B comes in. Our contract pharmacy makes it easy. We help you engage and recruit new pharmacies on your behalf. We’ll then work with these retail pharmacies to obtain proper registration with the Office of Pharmacy Affairs. We can also maximize your capture rate of eligible and profitable prescriptions, provide an ordering interface which gives your pharmacies more control and more visibility into 340B drug replenishments with no more unexpected deliveries or inventory swell. We also offer an enterprise view so that you can access data across your participating locations and provide reports tools and dashboards to give you a complete audit-ready view into your program performance and activity. If you want to take things further, you can leverage Specialty Contract Rx, our preferred Specialty and Infusion partnerships.

Purchase analytics

Annual hospital drug spending is rapidly increasing, this trend continues to negatively impact hospital costs, especially since Medicaid reimbursement isn’t keeping up. Verity Solutions purchase analytics platform can help. With purchase analytics, you can proactively monitor and analyze NDC pricing opportunities, enabling you to identify the optimal NDCs for significant savings. Purchase analytics provides your organization with savings regardless of which 340B wholesaler or administrator you use. It’s cloud-based, so there’s no software to download or maintain, it features built-in price trends and requires minimal staff resources to operate. With over 100,000 NDCS is impossible for covered entities to do an analysis manually. With the exception of a few high-value drugs, typically a buyer would purchase the cheapest GPO product, but is that really the best choice? With purchase analytics, you can identify a blended price and establish which NDC is the most cost effective for your organization. Remember the 340B price is not directly related to the GPO price. Purchase analytics helps you identify the lowest available drug prices based on your utilization. With purchase analytics, you can achieve savings of 10-13% across your total drug spend.

Verity Solutions would like to extend an invitation to visit us at the following websites to learn more about us and our 340B Third Party Administrator Services.

Visit us at the Virtual Pharmacy Trade Show by RXinsider

Find Us On!

LinkedIn - Verity340B.com - TPA 340B

Google+ - Verity340B.com - TPA 340B

Facebook - Verity340B.com - TPA 340B

#340B #340B Third Party Administrator #340bhealth

0 notes